We didn’t become the world leader in addiction treatment overnight. Our endeavor started small, with one singular focus – to intimately understand the journey of individuals suffering with addiction. People with addiction are often stereotyped and discounted, creating an environment where many are under-diagnosed, undertreated and under-supported. They’re often unaware of their treatment options, have limited access to treatment, or simply don’t seek it out because they’re afraid of being stigmatized.
Since our inception, we have actively partnered with healthcare professionals, the public health community, policymakers, and payers to humanize people suffering from addiction and to treat addiction as a chronic, relapsing medical condition rather than a social disorder. We believe that people with addiction should be treated as patients, just like sufferers other chronic diseases.
- Pharmaceuticals & Biotechnology
- 🇬🇧 United Kingdom
- £1.13 Friday's close
52 Week High0.0%15 February 2019
52 Week Low0.0%15 February 2019
Next Ex-Div-Date Countdown
|Ex-Div Date||Pay Date||Year||Type||Frequency||Status||Amount|
|17 Sep 2015||23 Oct 2015||2015||Interim||Semiannually||Paid||2.08p|
|16 Jun 2016||29 Jul 2016||2015||Final||Semiannually||Paid||7.3p|
|15 Sep 2016||21 Oct 2016||2016||Interim||Semiannually||Paid||2.3p|
|15 Jun 2017||28 Jul 2017||2016||Final||Semiannually||Paid||0p|
|14 Sep 2017||20 Oct 2017||2017||Interim||Semiannually||Paid||0p|
|14 Jun 2018||27 Jul 2018||2017||Final||Semiannually||Paid||0p|
|13 Sep 2018||19 Oct 2018||2018||Interim||Semiannually||Paid||0p|
Indivior optimized dividend - 12 month history
Indivior share price - 12 month history
Try the real thing now:
You currently don't have access this feature, however you can preview the functionality.
This is a fully-functional demo intended to showcase the usefulness of this product using old data.
By proceeding you acknowledge that shown here is old data for demonstration purposes only.
To immediately activate your free account and see the live data you can log in with Facebook or LinkedIn: